Get the Stockscreener App
1.64
5.75%
-0.10
After Hours:
1.71
0.07
+4.27%
Palisade Bio Inc stock is traded at $1.64, with a volume of 3.22M.
It is down -5.75% in the last 24 hours and up +9.33% over the past month.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
See More
Previous Close:
$1.74
Open:
$1.72
24h Volume:
3.22M
Relative Volume:
0.67
Market Cap:
$244.69M
Revenue:
-
Net Income/Loss:
$-14.07M
P/E Ratio:
-0.1172
EPS:
-13.99
Net Cash Flow:
$-12.56M
1W Performance:
-11.35%
1M Performance:
+9.33%
6M Performance:
+161.77%
1Y Performance:
+99.15%
1-Day Range:
$1.61
$1.76
1-Week Range:
$1.61
$1.85
52-Week Range:
$0.53
$2.64
Palisade Bio Inc Stock (PALI) Company Profile
Name
Palisade Bio Inc
Sector
Industry
Phone
(858) 704-4900
Address
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
1.64 | 259.61M | 0 | -14.07M | -12.56M | -13.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Palisade Bio Inc Stock (PALI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Initiated | B. Riley Securities | Buy |
| Dec-29-25 | Initiated | Piper Sandler | Overweight |
Palisade Bio Inc Stock (PALI) Latest News
Treasury Yields: Will Palisade Bio Inc benefit from current market trends2025 Winners & Losers & Community Consensus Trade Signals - baoquankhu1.vn
PALI SEC FilingsPalisade Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Short Interest in Palisade Bio, Inc. (NASDAQ:PALI) Rises By 20.2% - MarketBeat
Palisade Bio Announces Participation in Two Upcoming Investor Conferences - Bitget
Palisade Bio Details PALI-2108 UC, Crohn’s Plans and Cash Runway Into 2029 at Oppenheimer Conference - MarketBeat
Palisade Bio (NASDAQ:PALI) Upgraded to "Hold" at Wall Street Zen - MarketBeat
PALI Should I Buy - Intellectia AI
PALI: Advancing a once-daily, gut-restricted PDE4 inhibitor with strong funding and pivotal trials ahead - TradingView
Palisade Bio (NASDAQ:PALI) Now Covered by Stifel Nicolaus - MarketBeat
Stifel Initiates Palisade Bio at Buy With $5 Price Target - marketscreener.com
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Palisade Bio (PALI) Sees New 'Buy' Rating from Stifel | PALI Sto - GuruFocus
Stifel Initiates Coverage of Palisade Bio (PALI) with Buy Recommendation - Nasdaq
Stifel initiates Palisade Bio stock with buy rating on IBD drug - Investing.com South Africa
PALI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Stifel initiates Palisade Bio stock with buy rating on IBD drug By Investing.com - Investing.com Canada
Palisade Bio Strengthens Advisory Board, Fast-tracks Key Research Developments - timothysykes.com
Palisade Bio presents ulcerative colitis drug trial data at ECCO By Investing.com - Investing.com India
Palisade Bio presents ulcerative colitis drug trial data at ECCO - Investing.com
Palisade Bio, Inc. Presents Phase 1b Data Demonstrating Localized Target Engagement and Early Clinical Response of PALI-2108 in Ulcerative Colitis at ECCO 2026 - Quiver Quantitative
Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026 - Bitget
Palisade Bio Reports Rapid Clinical, Histologic and New - GlobeNewswire
Palisade Bio, Inc. (NASDAQ:PALI) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Palisade Bio, Inc. (NASDAQ:PALI) Sees Large Increase in Short Interest - Defense World
Palisade Bio appoints IBD expert to clinical advisory board By Investing.com - Investing.com Canada
Perceptive fund discloses 9.99% Palisade Bio (PALI) ownership stake - Stock Titan
Palisade Bio appoints IBD expert to clinical advisory board - Investing.com
Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board - Bitget
Palisade Bio Strengthens Clinical Advisory Board with Appointment of Dr. Bram Verstockt to Advance PALI-2108 Development in Ulcerative Colitis and Crohn's Disease - Quiver Quantitative
Ulcerative colitis drug PALI-2108 gets boost from new IBD advisor - Stock Titan
Palisade Bio (PALI) chief medical officer Jones sells $3480 in stock - Investing.com UK
Can Palisade Bio Inc. (7NS0) stock resist broad market declinesPortfolio Risk Report & Precise Trade Entry Recommendations - mfd.ru
Palisade Bio (PALI) chief medical officer Jones sells $3480 in stock By Investing.com - Investing.com Australia
Palisade Bio CEO Finley sells $6818 in shares - Investing.com South Africa
Palisade Bio CEO Finley sells $6818 in shares By Investing.com - Investing.com India
Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Can Palisade Bio Inc. maintain sales growthJuly 2025 Chart Watch & Accurate Buy Signal Notifications - mfd.ru
Palisade Bio (PALI) awards Chief Medical Officer 787,000 RSUs - Stock Titan
Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium - GlobeNewswire
Biotech Palisade Bio joins Piper Sandler talk on new immune targets - Stock Titan
Palisade Bio (NASDAQ:PALI) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Aug Shorts: Will Palisade Bio Inc outperform its industry peers2025 Retail Activity & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Aug Sentiment: Is Palisade Bio Inc stock a good pick for beginners2025 Volume Leaders & Safe Capital Investment Plans - baoquankhu1.vn
Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - marketscreener.com
Palisade Bio leaders set for virtual Oppenheimer healthcare conference slot - Stock Titan
Franklin Resources Inc's Strategic Acquisition of Palisade Bio I - GuruFocus
Palisade Bio (PALI) soars 5% ahead of clinical trial results - MSN
Can Palisade Bio Inc maintain sales growth2025 Sector Review & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Palisade Bio (PALI) upgraded to buy: Here's what you should know - MSN
Palisade Bio appoints two IBD experts to clinical advisory board By Investing.com - Investing.com South Africa
Palisade Bio Inc Stock (PALI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Palisade Bio Inc Stock (PALI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Finley John David | CEO, CFO |
Feb 12 '26 |
Sale |
1.75 |
3,896 |
6,818 |
27,353 |
| Williams Donald Allen | Director |
Jan 16 '26 |
Buy |
1.67 |
5,000 |
8,356 |
10,728 |
| Williams Donald Allen | Director |
Jan 09 '26 |
Buy |
1.88 |
5,000 |
9,400 |
5,728 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):